Browse the evidence

Ghrelin is an endogenous peptide hormone that stimulates food intake and growth hormone secretion, with its circulating levels inversely correlated with energy balance (increasing during fasting/starvation and decreasing during feeding/obesity).

Understand that hunger is biologically regulated by ghrelin, which rises when you are fasting or have low energy stores and falls after eating. In obesity, this system is often blunted, with lower baseline ghrelin levels, which may contribute to the difficulty in regulating food intake. Recognizing this hormonal drive can help separate biological hunger from emotional or habitual eating.

Ghrelin stimulates food intake and growth hormone release primarily through the vagus nerve and hypothalamic pathways (NPY/AgRP neurons), rather than solely by crossing the blood-brain barrier.

This mechanism suggests that gut health and vagal nerve integrity may influence hunger signals. While not directly actionable for most, it highlights that hunger signals are complex neural communications, not just simple blood chemistry.

Klotho protein functions as an anti-aging agent by inhibiting four major aging pathways (TGF-β, IGF-1, Wnt, NF-κB) and promoting antioxidant defenses, with deficiency leading to accelerated aging phenotypes and overexpression extending lifespan.

Maintaining healthy kidney function and managing metabolic health (blood sugar, blood pressure) may help preserve natural Klotho levels, which are linked to longevity. While direct Klotho supplementation is not yet a standard consumer intervention, lifestyle factors that support kidney health and reduce inflammation (like exercise and certain diets) are associated with higher Klotho expression.

Aging causes a progressive decline in brown adipose tissue (BAT) mass and thermogenic activity, primarily through mitochondrial dysfunction, reduced sympathetic nervous system stimulation, and hormonal shifts, leading to age-related metabolic alterations.

As you age, your body's ability to burn fat for heat (via brown fat) naturally declines due to changes in hormones, nerve signals, and cell health. This contributes to weight gain and metabolic issues. While you can't stop aging, understanding this process highlights the importance of maintaining metabolic health through lifestyle factors that may support remaining brown fat function, such as staying active and managing stress/hormonal health.

Beige adipose tissue formation declines with age due to defective progenitor cell proliferation and differentiation, potentially linked to changes in the adipose tissue microenvironment and reduced SIRT1 levels.

Your body's ability to create 'beige fat' (fat that burns energy) decreases as you age, partly because the stem cells that make it become less active. This is linked to changes in your body's internal environment and signaling molecules. While this decline is natural, it underscores the importance of maintaining overall metabolic health to support any remaining thermogenic capacity.

High responders to resistance exercise training exhibit suppressed mTOR signaling and down-regulation of ribosomal RNA genes, contradicting the canonical view that mTOR activation drives hypertrophy.

While resistance training is essential for muscle growth, the molecular mechanisms driving individual responses vary. The common belief that 'more mTOR activation equals more muscle' is challenged by evidence showing that high responders may actually have suppressed mTOR signaling. This suggests that personalized approaches to training and nutrition may be more effective than one-size-fits-all strategies focused solely on maximizing mTOR activation.

Muscle aging involves distinct molecular processes (post-transcriptional changes, PGR/RXR activation) that are separate from those regulated by physical activity.

Exercise is beneficial for muscle health, but it may not reverse the specific molecular changes associated with aging. Understanding these distinct pathways could lead to targeted therapies for age-related muscle loss (sarcopenia) that complement exercise.

Genetic variants in the leptin-melanocortin pathway (e.g., MC4R, PPARG) and adipokine genes (e.g., ADIPOQ) significantly influence the risk of developing obesity-associated comorbidities like type 2 diabetes and coronary heart disease, independent of total body weight.

If you have a family history of obesity or metabolic issues, get tested for genetic risk factors. This knowledge allows for earlier and more targeted monitoring of blood sugar and heart health, even if your weight is stable.

Obesity is not a sufficient cause of non-insulin-dependent diabetes mellitus (NIDDM); insulin resistance acts as the primary mechanistic link between obesity and diabetes risk, with genetic/familial factors accounting for significant variance in insulin action independent of body fat percentage.

Focus on insulin sensitivity, not just weight. While obesity increases risk, it does not guarantee diabetes. Genetic predisposition and the degree of insulin resistance are key. For those with high body fat, reducing fat mass helps, but for those with strong family history, monitoring insulin action (via glucose tolerance) is more important than BMI alone.

Skeletal muscle glycogen synthase activation is a critical determinant of insulin-mediated glucose disposal, and defects in this enzyme's activation by insulin (rather than glucose uptake alone) contribute to insulin resistance.

Exercise and diet improve insulin sensitivity partly by improving glycogen synthase function. Since this enzyme is activated by insulin, maintaining insulin sensitivity is key to efficient glucose storage as glycogen.

Leucine limitation in skeletal muscle cells induces autophagy and lysosome-dependent proteolysis through a signaling pathway that is independent of mTOR.

In differentiated muscle cells, a lack of leucine triggers muscle breakdown via autophagy through a pathway that does not involve mTOR. This suggests that muscle protein turnover is regulated by multiple distinct signaling mechanisms depending on the cell's state and the specific nutrient signal, rather than relying solely on the mTOR pathway.

Obesity-induced adipose tissue dysfunction and systemic insulin resistance drive the development of MAFLD/NASH, which in turn exacerbates cardiovascular disease risk through the release of pro-atherogenic, pro-coagulant, and pro-inflammatory mediators from the liver.

If you have fatty liver disease (MAFLD/NASH), your liver is actively sending chemical signals that increase your risk of heart disease and stroke, independent of your weight. Managing liver health through weight loss and metabolic control is critical for cardiovascular protection, not just liver protection.

Obesity causes structural and functional cardiac alterations, including left ventricular hypertrophy, diastolic dysfunction, and atrial fibrillation, primarily through increased blood volume, cardiac output, and neuro-hormonal activation (RAAS).

Excess body weight forces your heart to work harder by increasing blood volume and output, leading to thickening of the heart muscle (LVH) and stiffening of the heart chambers. This structural change happens even if you feel no symptoms and increases the risk of heart failure and arrhythmias like atrial fibrillation.

Elevated baseline serum levels of branched-chain (valine, leucine, isoleucine) and aromatic (phenylalanine, tyrosine) amino acids are strongly predictive of future type 2 diabetes development in Chinese populations, independent of conventional metabolic markers.

If you are of Chinese descent or have similar metabolic profiles (lower BMI but higher visceral fat), standard blood sugar tests may not reveal your diabetes risk until it is too late. Elevated levels of specific amino acids (valine, leucine, isoleucine, phenylalanine, tyrosine) appear years before clinical diagnosis. While not yet a standard clinical test, this suggests that individuals with a family history of diabetes should prioritize visceral fat reduction and metabolic health monitoring beyond just fasting glucose, as these metabolic shifts may precede clinical disease.

Metformin treatment increases DICER1 protein levels by promoting the nuclear translocation of the RNA-binding protein AUF1, which stabilizes DICER1 mRNA and leads to the upregulation of specific microRNAs (e.g., miR-34a, miR-125) that inhibit cellular senescence.

Metformin, used for type 2 diabetes, appears to slow cellular aging by stabilizing a protein called DICER1. This stabilization allows the cell to produce specific microRNAs that prevent cells from becoming 'zombie' senescent cells, which drive inflammation and aging. This effect is observed at standard therapeutic doses in humans and equivalent doses in mice, suggesting it may contribute to the drug's potential anti-aging benefits beyond glucose control.

High-fat diet-induced obesity reduces intestinal IgA+ immune cells and secretory IgA, which exacerbates insulin resistance by increasing intestinal permeability, microbial encroachment, and systemic inflammation.

Maintaining gut immune health, specifically IgA levels, may be crucial for managing insulin resistance during high-fat diets. While this study is in mice, it suggests that interventions supporting gut immunity (like certain diets or therapies) might help metabolic health.

Current glucose-lowering therapies, specifically metformin and bariatric surgery, alter intestinal IgA+ B cell populations and fecal secretory IgA levels, respectively.

If you are taking metformin or had bariatric surgery, part of their benefit may come from restoring gut IgA levels, which helps control inflammation and glucose.

Adipokines such as leptin and adiponectin serve as critical biomarkers for visceral fat distribution, insulin sensitivity, and metabolic risk, with altered secretion patterns linking obesity to cardiovascular and metabolic diseases.

Your fat tissue is not just storage; it actively sends hormonal signals that affect your insulin sensitivity and heart health. Understanding this link helps explain why weight loss and metabolic health are interconnected, and why measuring certain biomarkers (like adiponectin or leptin) can provide insights into your metabolic risk beyond just weight.

Exogenous leptin administration is an effective treatment for genetic leptin deficiency and lipodystrophy, but fails to significantly reduce body weight in common obesity due to central leptin resistance.

Leptin therapy is not a weight loss solution for typical obesity because your body has become resistant to its signals. It is, however, a life-saving treatment for rare conditions like lipodystrophy or genetic leptin deficiency where the body lacks this hormone entirely.

The hypothalamus regulates basal metabolic rate (RMR) and adaptive thermogenesis through distinct neuronal populations and hormonal axes, with lean mass and thyroid hormone signaling being primary determinants of energy expenditure.

Focus on preserving lean muscle mass, as it is the largest driver of your resting metabolic rate. Your brain's hypothalamus regulates your baseline calorie burn through hormonal signals (like thyroid and leptin) and neural pathways. While exercise matters, your body's internal 'thermostat' sets the stage for how efficiently you burn energy at rest.

Older adults exhibit blunted muscle hypertrophy in response to resistance exercise training due to synchronous deficits in long-term muscle protein synthesis and ribosomal biogenesis, rather than just acute signaling issues.

If you are older, expect your muscles to grow slower than when you were young. This is a biological reality called 'anabolic resistance,' driven by hormonal changes and cellular efficiency, not a lack of effort. Focus on consistency and strength gains, which older adults can still achieve significantly, even if muscle size increases are blunted compared to younger individuals.

Elevated intracellular ceramide levels induce cellular senescence and contribute to age-related pathologies such as insulin resistance and atherosclerosis, whereas sphingosine-1-phosphate (S1P) delays senescence and promotes cell survival.

This research highlights that cellular aging is driven by specific lipid signals: high ceramide promotes aging/senescence, while S1P promotes youth/survival. While this paper does not prescribe a specific diet, it implies that interventions which lower ceramide or boost S1P (potentially through specific dietary fats or metabolic health) could theoretically delay aging. Focus on metabolic health to maintain favorable sphingolipid balances.

Ceramide accumulation in specific tissues (adipose, liver, muscle) during aging and high-fat diet consumption drives insulin resistance and inflammation, linking sphingolipid metabolism to type 2 diabetes.

High levels of specific lipids called ceramides, particularly C16-ceramide, are linked to insulin resistance and type 2 diabetes. This suggests that managing lipid metabolism and reducing the production of these specific lipids (potentially through diet and exercise) may help prevent or manage insulin resistance.

Low leptin levels during weight loss increase brain activity in regions involved in emotional, cognitive, and sensory control of food intake, driving the desire to eat.

When you lose weight, your brain changes how it processes food images, making them more appealing and triggering decision-making areas associated with craving. This is a biological response to low leptin, not just a failure of willpower.